Literature DB >> 1353584

Vigabatrin for startle-disease with altered cerebrospinal-fluid free gamma-aminobutyric acid.

J B Stephenson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1353584     DOI： 10.1016/0140-6736(92)91515-a

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Antiepileptic drugs for the treatment of post-traumatic stress disorder.

Authors:  Heather A Berlin
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

2.  A case of glycine-receptor antibody-associated encephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings.

Authors:  A Piotrowicz; A Thümen; M I Leite; A Vincent; A Moser
Journal:  J Neurol       Date:  2011-05-04       Impact factor: 4.849

Review 3.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 4.  Autoimmune synaptopathies.

Authors:  Sarah J Crisp; Dimitri M Kullmann; Angela Vincent
Journal:  Nat Rev Neurosci       Date:  2016-02       Impact factor: 34.870
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.